Skip to Content

Drug interactions between Genvoya and Stribild

Results for the following 2 drugs:
Genvoya (cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide)
Stribild (cobicistat/elvitegravir/emtricitabine/tenofovir)

Interactions between your drugs

There were no interactions found in our database between Genvoya and Stribild - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.

Genvoya

A total of 884 drugs (5227 brand and generic names) are known to interact with Genvoya.

Stribild

A total of 884 drugs (5227 brand and generic names) are known to interact with Stribild.

Drug and food interactions

Moderate

elvitegravir food

Applies to: Genvoya (cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide) and Stribild (cobicistat / elvitegravir / emtricitabine / tenofovir)

Food significantly increases the absorption of elvitegravir. You should take each dose of elvitegravir with a meal. Taking it on an empty stomach may lead to inadequate blood levels and reduced effectiveness of the medication in treating HIV infection.

Switch to professional interaction data

Minor

tenofovir food

Applies to: Genvoya (cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide) and Stribild (cobicistat / elvitegravir / emtricitabine / tenofovir)

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

For clinical details see professional interaction data.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Antiviral boosters

Therapeutic duplication

The recommended maximum number of medicines in the 'antiviral boosters' category to be taken concurrently is usually one. Your list includes one medicines belonging to the 'antiviral boosters' category:

  • cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide
  • cobicistat/elvitegravir/emtricitabine/tenofovir

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Duplication

Integrase strand transfer inhibitors

Therapeutic duplication

The recommended maximum number of medicines in the 'integrase strand transfer inhibitors' category to be taken concurrently is usually one. Your list includes one medicines belonging to the 'integrase strand transfer inhibitors' category:

  • cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide
  • cobicistat/elvitegravir/emtricitabine/tenofovir

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Drug Interaction Classification

The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide